Literature DB >> 9078826

Adenosine deaminase activity in nephrotic syndrome.

O P Mishra1, R Garg, Z Ali.   

Abstract

Cell-mediated immunity (CMI) was evaluated in 40 children with idiopathic nephrotic syndrome and 20 healthy controls. The significantly decreased response to purified protein derivative (PPD)(P < 0.001), absolute lymphocyte count (ALC) (P < 0.02), T-lymphocytes percentage (P < 0.001) and elevated serum adenosine daminase (ADA) activity (P < 0.001) were observed in patients with active nephrotic syndrome (ANS) in comparison to controls. The overall mean values of T-lymphocytes percentage and ADA activity in ANS patients were 73.7 and 213.7 per cent of normal mean, respectively. A significant negative correlation was observed between the two parameters (r = -0.5649, P < 0.001). In remission, the ALC and T-lymphocytes percentage showed significant increase in levels in comparison to their corresponding ANS values (P < 0.05 and P < 0.001, respectively), but the latter remained significantly lower when compared with controls (P < 0.001). The ADA activity did not differ significantly in comparison to corresponding ANS level. Thus, impaired CMI was observed both in active, as well as in remission stage of the disease and ADA activity demonstrated a more pronounced change than other parameters.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9078826     DOI: 10.1093/tropej/43.1.33

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  2 in total

1.  Lymphocyte adenosine deaminase activity in children with idiopathic nephrotic syndrome.

Authors:  Om P Mishra; Jayant Ghosh; Ziledar Ali; Malay Sen; Rajniti Prasad
Journal:  Pediatr Nephrol       Date:  2005-08-13       Impact factor: 3.714

2.  Adenosine deaminase activity in type 2 diabetes mellitus: does it have any role?

Authors:  A Niraula; S Thapa; S Kunwar; M Lamsal; N Baral; R Maskey
Journal:  BMC Endocr Disord       Date:  2018-08-20       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.